Anything wrong with Xifaxan? Maybe family physicians don't trust it? Maybe stock should take a couple of tablets? <g> (Sorry, couldn't resist, while our money runs away like -censored-.)
RALEIGH, N.C.--(BUSINESS WIRE)--Oct. 14, 2004--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today reported on Company-related activities that will take place over the next several days at the 2004 Annual Scientific Assembly of the American Academy of Family Physicians (AAFP) in Orlando, FL. AAFP 2004 will provide a venue for Salix to introduce XIFAXAN(TM) (rifaximin) tablets 200 mg to more than 94,000 primary health care providers.
Salix is supporting, by means of an unrestricted educational grant, a continuing educational symposium for general practitioners entitled: "New Perspectives in Managing Infectious Diarrhea in the Traveler: A Focus on Prevention and Post-Infectious Complications." A faculty of nationally recognized key opinion leaders comprised of Robert E. Rakel, M.D., Herbert L. DuPont, M.D. and Henry Lin, M.D. will address issues related to the epidemiology, diagnosis and current and new management strategies for travelers' diarrhea.
Commenting on the Company's presence and activities at AAFP, Ms. Carolyn Logan, President and CEO, stated, "Salix looks forward to this first opportunity to meet face-to-face with and introduce XIFAXAN to family physicians. We anticipate that these primary care providers will be very receptive to XIFAXAN, a nonabsorbed, gut-selective antibiotic, as a significant new addition to currently available systemic antibiotic therapy for the treatment of travelers' diarrhea."
AI
Market Data 
Markets 
